Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Alpha-synuclein is a 140 aa neuronal protein pathologically and genetically linked to Parkinson's disease (PD). In PD, the major protein modification of alpha-synuclein is phosphorylation at serine 129. Alpha-synuclein phosphorylation also occurs at low levels in normal brains and cultured CNS neurons, but its regulation and role are only beginning to be investigated. The enteric nervous system is now recognized as a second brain in its own right, and therefore, we set out to examine the regulation of alpha-synuclein phosphorylation in enteric neurons. To this end, primary cultures of rat enteric nervous system (ENS) and enteric neurons, which both express alpha-synuclein, were either depolarized or treated with forskolin and analyzed by western blot. We found that membrane depolarization and forskolin induced alpha-synuclein phosphorylation via a Ca-calmodulin-dependent protein kinase and cAMP/exchange protein directly activated by cyclic AMP (EPAC) signaling pathway, respectively. Both pathways converged on Polo-like kinase 2 (PLK2) to phosphorylate alpha-synuclein. PLK2 inhibition increased the amount of alpha-synuclein secretion while reducing its intracellular phosphorylation level in both cytoplasmic and membranous fractions. To investigate alpha-synuclein phosphorylation in the ENS further, specimens of human colon were analyzed to show that the distribution of phosphorylated alpha-synuclein in the ENS was highly variable and that the amount of soluble phosphorylated alpha-synuclein did not differ between PD and control subjects. Our study is the first to show that alpha-synuclein phosphorylation can be regulated in enteric neurons, providing a basis to unravel the functions of alpha-synuclein and its phosphorylation in the ENS.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejn.70198DOI Listing

Publication Analysis

Top Keywords

alpha-synuclein phosphorylation
32
enteric neurons
16
alpha-synuclein
14
phosphorylation
9
regulation alpha-synuclein
8
phosphorylation enteric
8
enteric nervous
8
nervous system
8
phosphorylation ens
8
phosphorylated alpha-synuclein
8

Similar Publications

This review covers recent advances (2023-2024) in neuroimaging research into the pathophysiology, progression, and treatment of Alzheimer's disease (AD) and related dementias (ADRD). Despite the rapid emergence of blood-based biomarkers, neuroimaging continues to be a vital area of research in ADRD. Here, we discuss neuroimaging as a powerful tool to topographically visualize and quantify amyloid, tau, neurodegeneration, inflammation, and vascular disease in the brain.

View Article and Find Full Text PDF

Introduction: Dysfunction of the glymphatic system is thought to lead to build up of toxic proteins including β-amyloid and α-synuclein, and thus may be involved in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). The Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS) index has been proposed as a marker of glymphatic function.

Aims: To investigate DTI-ALPS in mild cognitive impairment (MCI) and dementia, and determine its relationship with cognitive decline, and biomarkers of neurodegeneration.

View Article and Find Full Text PDF

Background And Objectives: α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.

View Article and Find Full Text PDF

An early diagnosis of Parkinson's disease (PD) represents a challenge and novel accurate biomarkers are therefore urgently needed. Detection of phosphorylated α-synuclein (p-α-syn) in skin nerve fibers has shown promise as such a marker. However, its accuracy for the identification of PD among patients with early signs of parkinsonism has not been thoroughly explored.

View Article and Find Full Text PDF

Animal models of the pathology of Parkinson's disease (PD) have provided most of the treatments to date, but the disease is restricted to human patients. In vitro models using human pluripotent stem cells (hPSCs)-derived neural organoids have provided improved access to study PD etiology. This study established a method to generate human striatal-midbrain assembloids (hSMAs) from hPSCs for modeling alpha-synuclein (α-syn) propagation and recapitulating basal ganglia circuits, including nigrostriatal and striatonigral pathways.

View Article and Find Full Text PDF